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The Impact of the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003
___________________________________________________________________
Given the complexity of the approximately seven hundred pages that make up the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, we are
providing a snapshot summary describing the legislation’s impact on the key
stakeholders.
Medicare Beneficiaries
In general, there is a significant expansion of benefits in terms of pharmacy benefits,
managed care plan options, and preventive care coverage. Medicare will now cover
initial preventative physical examinations in addition to screening services such as
pelvic exams, prostate cancer screening, colorectal cancer screening, diabetes
outpatient self-management, bone mass measurement, glaucoma screening, and
cardiovascular and diabetes screening tests. There are also demonstration programs
scheduled for certain new benefits which include additional chiropractic services,
adult day care services, consumer-directed chronic outpatient services, continuity
care for chronic patients, small provider technical assistance services, beneficiary
outreach services through Social Security offices, and pediatric palliative care.
Managed Care Plans
The Medicare+Choice program is renamed the Medicare Advantage program. There
are both near-term payment increases as well as additional funds totaling $12 billion
to entice plans into the Medicare Advantage program beginning in 2006. Despite
these positive improvements, it is important to remember that the government has
not always been a great business partner. The concern is that tight budgets would
lead to payment cuts and revisions that would reduce the attractiveness of
participating in the Medicare Advantage program in the future.
Physicians
Rather than the expected 4.5% payment cut due in 2004, physicians will see a
minimum payment increase of 1.5% in 2004 and 2005. For oncologists and others
that provide Medicare-covered drugs, Medicare payment for Part B-covered drugs
will be reduced from the current 95% of average wholesale price to 106% of average
sales price. In addition, payments could be reduced further to a “widely available
market price” where appropriate.
Rural Physicians
The bill provides for a substantial increase for rural physicians in the form of a floor
on physician geographic work index, which will result in approximately one billion
dollars in additional payments over ten years. There is also a five percent bonus for
physician payments in “scarcity areas.”
Pharmaceutical Manufacturers
As a result of the Medicare Pharmacy Benefit, there will be an increase in the
demand for both name brand and generic medications. In addition, the bill
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specifically prohibits the federal government from imposing price controls and limits
the ability of prescription drug plans to control utilization through formulary
restrictions. It allows drug re-importation from Canada only, and only after the
Secretary of Health and Human Services certifies that reimportation is safe and
provides for cost savings—a move that is unlikely to happen.
Hospitals
Hospitals that agree to submit quality outcome data to the Centers for Medicare and
Medicaid Services will receive a full market basket update for the next several years.
Graduate medical education payments will be reduced through the expansion of the
limitation on high cost programs, although indirect medical education subsidy
payments are increased by $400 million.
Long-term Care (LTC) Facilities
LTC facilities may experience some benefits as a result of Medicare relieving the
state burden of a percentage of their prescription drug costs now that Medicare is the
payor for prescriptions rather than Medicaid. In addition, the therapy cap will not be
applied for at least two years.
Hospice Agencies
Nurse practitioners will now be recognized as attending physicians for hospice
patients. Also, hospice consultation services provided by a physician will be covered
under Medicare. Examples of these services include evaluating for pain and symptom
management, counseling with respect to end-of-life care, and advising on advanced
care planning.
Home Health Agencies
In addition to a decrease in payments, there is additional concern for future Medicare
payments, as the bill calls for MedPAC to study home health profit margins, which is
expected to result in further cuts. On a slightly positive note, Medicare has
suspended the requirement for OASIS data collection for non-Medicare and Medicaid
patients.
Ambulatory Surgical Centers (ASC)
ASCs will see an immediate payment reduction, as well as a long-term freeze in
payments rates. In addition, ASCs will move toward a new prospective payment
system.
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